We analyzed RNA sequencing data of 430 clinically annotated AML samples and identified HMGA2 as a new candidate prognostic marker. This marker was successfully developed and validated as an RT-qPCR test to facilitate implementation in clinical laboratories. High HMGA2 expression adds significant independent prognostic value to known clinical and genetic prognostic factors in AML, and is predictive of poor clinical outcomes with standard AML therapies (Marquis M et al, Blood Cancer J, 2018). This test complements current AML tests to improve treatment orientation and can be integrated in ongoing and future prospective clinical trials studying innovative therapies to increase survival of HMGA2 positive AML patients.